Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

View all journals
Search
Log in

nature
search

Search

Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

British Journal of Cancer (2)
Nature Medicine (2)

Choose more journals

Article type Check one or more article types to show results from those article types only.

Research (3)
Amendments and Corrections (1)

Subject Check one or more subjects to show results from those subjects only.

Cancer
Medical research
Oncology

Date Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
Last 12 months
Last 2 years
Last 5 years

Custom date range

Clear all filters

Sort by:

Relevance

Date published (new to old)

Date published (old to new)

Showing 1–4 of 4 results

Advanced filters: Author: Kyriakos P Papadopoulos Clear advanced filters

Author Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

Toni K. Choueiri
Todd M. Bauer
Eric Jonasch
Amendments and Corrections27 Aug 2021
Nature Medicine

Volume: 27, P: 1849
Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis

A first-in-human trial of hypoxia-inducible factor (HIF)-2α inhibitor belzutifan (MK-6482) has a favorable safety profile and shows promising clinical activity for the treatment of patients with renal cell carcinoma who have been heavily pre-treated.

Toni K. Choueiri
Todd M. Bauer
Eric Jonasch
Research22 Apr 2021
Nature Medicine

Volume: 27, P: 802-805
Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma

Vincenzo Mazzaferro
Bassel F. El-Rayes
Walid L. Shaib
ResearchOpen Access13 Nov 2018
British Journal of Cancer

Volume: 120, P: 165-171
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor

Johanna C Bendell
Milind Javle
Amita Patnaik
ResearchOpen Access02 Feb 2017
British Journal of Cancer

Volume: 116, P: 575-583